Lilly's retatrutide suits described as a new enforcement playbook

Eli Lilly filed six federal lawsuits on August 12, 2026, against businesses it accuses of illegally selling retatrutide, an experimental obesity drug that has never been approved anywhere in the world ^[1][2]. A legal analysis of the suits says they target four "research-use-only" peptide sellers, one med spa, and one compounding pharmacy, and describes the filings as a new enforcement template aimed at gray-market sellers of unapproved molecules ^[1].

Retatrutide is a triple hormone agonist still in Phase 3 trials for obesity, type 2 diabetes and related conditions ^[2]. Lilly does not expect to submit it for FDA approval until early 2027 ^[1][2]. Because it has never been approved and has never been in shortage, no compounding exception has ever applied to it, and the FDA has stated retatrutide "cannot be used in compounding under federal law" ^[1]. The analysis notes retatrutide is not a component of any FDA-approved drug, does not appear on the FDA's list of bulk substances allowed for compounding, and has no USP or NF monograph, so there is "no gray zone" for the defendants ^[1].

The complaints allege the four RUO sellers labeled products "research use only" — a designation meant for lab work, not human use — while marketing them in ways aimed at people, and that the med spa defendant openly advertised a "Triple G" retatrutide product on its website and social media ^[1]. Lilly argues these businesses "are not practicing medicine; they are selling illegal drugs," and warns that because the products are unregulated they may be fake, impure or mis-dosed ^[1]. The six cases were filed in four federal district courts in Texas ^[1].

The lawsuits are part of a much larger effort. Lilly says it has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, law enforcement and licensing boards, and has flagged more than 14,000 websites, ads and listings marketing retatrutide across more than 100 countries ^[1][2]. Notably, the suits rely almost entirely on state consumer-protection and unfair-competition laws in states including Texas, Tennessee, Washington, North Carolina, South Carolina, Colorado, Connecticut and Alaska, rather than patent or federal trademark claims, with only one Lanham Act false-advertising claim, against the med spa Aesthetic Envy ^[1].

Why it matters for patients

People considering retatrutide from a peptide seller, med spa or compounder should know there is currently no legal channel to buy it as a finished product for personal use in the United States ^[1][2]. The only lawful ways to access real retatrutide right now are enrollment in a Lilly clinical trial or, in narrow cases, an expanded access program Lilly set up for patients who meet specific medical criteria and cannot join a trial ^[2]. Products sold outside those channels are unregulated, meaning there is no guarantee of what is actually in the vial, at what strength, or whether it is contaminated ^[1]. Because retatrutide has not been reviewed by the FDA under any pathway, its safety and effectiveness for human use have not been established outside of clinical trials.

The legal risk in this space is also shifting. Earlier disputes over compounded tirzepatide and semaglutide centered on whether a shortage still justified compounding exceptions. Retatrutide has never qualified for any such exception, so sellers and buyers are operating in what the analysis calls a much clearer-cut violation of federal law ^[1].

What happens next

Lilly plans to submit retatrutide for FDA approval in early 2027 ^[1][2]. Until then, the company says it will keep pressing regulators, law enforcement, and online and payment platforms to shut down unauthorized sales ^[2]. A separate, unresolved regulatory question is whether retatrutide will ultimately be classified as a conventional drug or as a biological product, a distinction that would affect whether any compounding exemptions could ever apply to it after approval ^[1].